Clinical trials: Pituitary Disorders
Endogenous Cushing's Syndrome
Treatment for Endogenous Cushing's Syndrome
The primary objectives of this study are to evaluate the clinical responder rate, defined as the proportion of subjects with normal UFC after 6 months of treatment with COR-003 in the Maintenance Phase without dose increase, and…
- Trial name
- SONICS (NCT01838551)
- Testing
- Levoketoconazole
- Where
- 42 sites in United States, Belgium and 13 more
- Volunteers
- 94 people
- Sponsor
- Cortendo AB
Osteopenia
Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density
The purpose of this project is to evaluate the hypothesis that bisphosphonate treatment given to growth hormone deficient patients (regardless of current growth hormone replacement therapy status and without changing that status)…
- Trial name
- NCT00145704
- Testing
- bisphosphonate therapy (risedronate), Vitamin D supplement, Calcium
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- State University of New York - Upstate Medical University
Growth Hormone, Recombinant, Fatty Liver
The Effect of Growth Hormone Replacement on Liver Fat
We will examine a cohort of growth hormone deficient adults starting growth hormone (GH) replacement. The purpose of this study is to determine whether GH replacement reduces the fat content of the liver.
- Trial name
- NCT00774579
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Imperial College London
Acromegaly
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
The patients received either Pasireotide LAR or Octreotide LAR for one year of treatment. The objective of this study was to compare the proportion of patients with a reduction of mean GH level to <2.5 µg/L and the normalization…
- Trial name
- NCT00600886
- Testing
- Pasireotide, Octreotide
- Where
- 95 sites in United States, Argentina and 25 more
- Volunteers
- 358 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly, Pituitary Gigantism
Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
To evaluate efficacy, safety, pharmacokinetics and pharmacodynamics of pasireotide LAR in Japanese patients with active acromegaly or pituitary gigantism.
- Trial name
- NCT01673646
- Testing
- Pasireotide LAR
- Where
- 27 sites in Japan
- Volunteers
- 33 people
- Sponsor
- Novartis Pharmaceuticals
Syndrome of Inappropriate Antidiuretic Hormone Secretion
A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH
The objective of this study is to investigate the efficacy and safety of tolvaptan based on the change in serum sodium concentration following administration of tolvaptan oral tablets at 7.5 to 60 mg/day for up to 30 days in…
- Trial name
- NCT03048747
- Testing
- Tolvaptan Oral Tablet
- Where
- 6 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Growth Hormone Deficiency
Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency
Treatment of children with growth failure due to growth hormone deficiency (GHD). Primary • To evaluate the efficacy and safety of weekly MOD-4023 administration compared to daily Genotropin® administration in Japanese…
- Trial name
- NCT03874013
- Testing
- MOD-4023, Genotropin
- Where
- 46 sites in Japan
- Volunteers
- 44 people
- Sponsor
- OPKO Health, Inc.
Rhinitis, Allergic, Perennial and/or Seasonal
Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis
The primary objective was to evaluate the effect of a 6-week treatment with TAA-AQ (110 μg) and TAA-AQ (220 μg) once daily (QD) versus placebo on hypothalamic-pituitary-adrenal (HPA) axis function as measured by serum cortisol…
- Trial name
- NCT01154153
- Testing
- Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ), Claritin® Syrup
- Where
- 8 sites in United States
- Volunteers
- 140 people
- Sponsor
- Sanofi
Pituitary Tumors
Barrow Nasal Inventory Survey
The purpose of this study is to evaluate patient nasal outcome following endo-nasal surgery. This type of surgery is conducted for pituitary and skull base tumors.
- Trial name
- BNI (NCT01322945)
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Acromegaly
Programme of Acromegaly Screening in Patients With Associated Somatic Disorders
The primary objective of the protocol is to define percentage of patients with acromegaly in relation to the total number of screened patients with confirmed clinically significant set of associated somatic disorders with the…
- Trial name
- ACROSCREEN (NCT02020967)
- Testing
- Non-interventional cross-sectional survey
- Where
- 2 sites in Russia
- Volunteers
- 367 people
- Sponsor
- Ipsen
Growth Hormone Deficiency
Cross Over Convenience And Preference Study Of New Mark VII Compared To Genotropin Pen In Pediatric And Adult Subjects
Convenience and preference for the new Mark VII pen compared to the current Genotropin pen will be assessed using a questionaire. it is expected that the new pen will be preferred or at least no different to the current pen.
- Trial name
- CHOOSE (NCT01112865)
- Testing
- Genotropin Pen, MARK VII pen
- Where
- 23 sites in Czechia, Germany and 5 more
- Volunteers
- 120 people
- Sponsor
- Pfizer
Acromegaly
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with…
- Trial name
- PATHFNDR-2 (NCT05192382)
- Testing
- Paltusotine
- Where
- 57 sites in United States, Argentina and 13 more
- Volunteers
- 111 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Hypertension, End Stage Renal Disease
Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease
The death rate of patients with endstage renal disease (ESRD) on dialysis each year is 20%, with diseases related to the heart and blood vessels causing about half.
- Trial name
- NCT01247090
- Testing
- Vasopressin - Very Low Dose, Vasopressin - Low Dose
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Columbia University
Asthma
Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis
The purpose of this study is to assess the effect of six weeks' treatment with two once-daily strengths of Fluticasone Furoate/GW642444 Inhalation Powder on the HPA axis system
- Trial name
- NCT01086410
- Testing
- Fluticasone Furoate/GW642444 Inhalation Powder, Prednisolone Oral Capsule
- Where
- 17 sites in United States, Germany and 1 more
- Volunteers
- 185 people
- Sponsor
- GlaxoSmithKline
Hyperprolactinemia, Hypogonadism
Administration of Kisspeptin in Patients With Hyperprolactinemia
The goal of this study is to learn more about how kisspeptin, a naturally occurring hormone, affects women with high levels of prolactin (also called hyperprolactinemia).
- Trial name
- NCT02956447
- Testing
- Kisspeptin 112-121, GnRH
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Massachusetts General Hospital
ADHD, ADD
ADHD Electrophysiological Subtypes and Implications in Transcranial Direct-current Stimulation
In the present study the aim is to examine whether transcranial direct-current stimulation (tDCS) generated excitability changes and induce modifications of functional cortical architecture in Attention Deficit Hyperactivity…
- Trial name
- tdcs&adhd (NCT01649232)
- Testing
- Active tDCS
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Spanish Foundation for Neurometrics Development
Adult Growth Hormone Deficiency
A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency
This will be a randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adult subjects with GHD to assess the safety and efficacy of a long-acting, once weekly injection of modified hGH (MOD-4023).
- Trial name
- NCT01909479
- Testing
- MOD-4023
- Where
- Israel
- Volunteers
- 202 people
- Sponsor
- OPKO Health, Inc.
Perennial Allergic Rhinitis, PAR
Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, safety study of the effects of ciclesonide nasal aerosol (74 mcg) on the HPA axis when administered once daily to male and premenarchal female…
- Trial name
- NCT01378429
- Testing
- ciclesonide nasal aerosol
- Where
- 7 sites in United States
- Volunteers
- 89 people
- Sponsor
- Sumitomo Pharma America, Inc.
Acromegaly
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
The purpose of this trial is to assess the efficacy and safety of CAM2029 in patients with acromegaly. Patients will be randomized to either CAM2029 or placebo administered subcutaneously once monthly during 6 months.
- Trial name
- ACROINNOVA 1 (NCT04076462)
- Testing
- CAM2029 (octreotide subcutaneous depot)
- Where
- 63 sites in United States, Germany and 8 more
- Volunteers
- 72 people
- Sponsor
- Camurus AB
Hyperprolactinemia, Prolactinoma
Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole
The purpose of this study is to evaluate the use of the non-ergoline dopamine agonist ropinirole for the treatment of hyperprolactinemia in patients with idiopathic hyperprolactinemia and prolactinomas.
- Trial name
- NCT03038308
- Testing
- Ropinirole
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Columbia University